Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients

Medicine (United States)

Volumn 95, Issue 40, 2016, Pages

  Wu, Chao Yi ^a,b   Yang, Huang Yu ^b,c   Yao, Tsung Chieh ^a,b   Liu, Su Hsun ^b,c   Huang, Jing Long ^a,b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Biomarker; Interleukin 18; Lupus nephritis; Systemic lupus erythematosus; Treatment response

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DOUBLE STRANDED DNA ANTIBODY; HEMOGLOBIN; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; SERUM ALBUMIN; BIOLOGICAL MARKER;

ARTICLE; CHILD; CLINICAL OUTCOME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ADOLESCENT; BIOPSY; BLOOD; COMPLICATION; DISEASE COURSE; FORECASTING; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; URINE;

ADOLESCENT; BIOMARKERS; BIOPSY; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INTERLEUKIN-18; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84995610399     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005037     Document Type: Article

References (70)

1. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am 2002;28:561-77. vi-vii.
2. Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010;36: 53-80. vii-viii.
3. Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
4. Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556-62.
5. Thakur N, Rai N, Batra P. Pediatric lupus nephritis-review of literature. Curr Rheumatol Rev 2016.
6. Sato VA, Marques ID, Goldenstein PT, et al. Lupus nephritis is more severe in children and adolescents than in older adults. Lupus 2012;21:978-83.
7. Huang JL, Yeh KW, Yao TC, et al. Pediatric lupus in Asia. Lupus 2010;19:1414-8.
8. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007;22:222-31.
9. Baqi N, Moazami S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996;7:924-9.
10. Yang LY, Chen WP, Lin CY. Lupus nephritis in children-a review of 167 patients. Pediatrics 1994;94:335-40.
11. Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus 2008;17:683-6.
12. Wong SN, Tse KC, Lee TL, et al. Lupus nephritis in Chinese children-a territory-wide cohort study in Hong Kong. Pediatr Nephrol 2006; 21:1104-12.
13. Pattaragarn A, Sumboonnanonda A, Parichatikanond P, et al. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients. J Med Assoc Thai 2005;88(Suppl 8):S232-241.
14. Boraschi D, Dinarello CA. IL-18 in autoimmunity: review. Eur Cytokine Netw 2006;17:224-52.
15. Shimizu C, Fujita T, Fuke Y, et al. High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. Mod Rheumatol 2012;22:73-9.
16. Migliorini P, Anzilotti C, Pratesi F, et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010;21:264-71.
17. Favilli F, Anzilotti C, Martinelli L, et al. IL-18 activity in systemic lupus erythematosus. Ann N Y Acad Sci 2009;1173:301-9.
18. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999;103(1 Pt 1):11-24.
19. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88.
20. Xu D, Trajkovic V, Hunter D, et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000;30:3147-56.
21. Nold M, Goede A, Eberhardt W, et al. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol 2003;367:68-75.
22. Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells andmouse spleen cells. Proc Natl Acad Sci U S A 1999;96:2256-61.
23. Gu Y, Kuida K, Tsutsui H, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997;275:206-9.
24. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFNgamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997;386:619-23.
25. Kahlenberg JM, Kaplan MJ. The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol 2014;26:475-81.
26. Wong CK, Li EK, Ho CY, et al. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000;39:1078-81.
27. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
28. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
29. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
30. Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev 2012;12:174-94.
31. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
32. Austin HA3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
33. Boumpas DT, Austin HA3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
34. Wu JY, Yeh KW, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 2014;43:513-20.
35. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 2012;64: 375-83.
36. Ruggiero B, Vivarelli M, Gianviti A, et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant 2013;28:1487-96.
37. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response CriteriaThe American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
38. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
39. Esfandiari E, McInnes IB, Lindop G, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 2001;167:5338-47.
40. Amerio P, Frezzolini A, Abeni D, et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002;20:535-8.
41. Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 2004; 23:225-9.
42. Wong CK, Ho CY, Li EK, et al. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol 2002;130:345-51.
43. Calvani N, Richards HB, Tucci M, et al. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 2004;138:171-8.
44. Calvani N, Tucci M, Richards HB, et al. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 2005;4:542-8.
45. Bossu P, Neumann D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci U S A 2003;100:14181-6.
46. Liu X, Bao C, Hu D. Elevated interleukin-18 and skewed Th1:Th2 immune response in lupus nephritis. Rheumatol Int 2012;32:223-9.
47. Hu D, LiuX, Chen S, et al. Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients. Clin Rheumatol 2010;29:717-21.
48. Fantuzzi G, Puren AJ, Harding MW, et al. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. Blood 1998;91:2118-25.
49. Pontillo A, Girardelli M, Kamada AJ, et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012;45:271-8.
50. Kahlenberg JM, Carmona-Rivera C, Smith CK, et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013;190: 1217-26.
51. Shin MS, Kang Y, Lee N, et al. U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. J Immunol 2012;188:4769-75.
52. Shin MS, Kang Y, Lee N, et al. Self double-stranded (ds)DNA induces IL-1beta production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol 2013;190:1407-15.
53. Zhao J, Zhang H, Huang Y, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation. Int Immunopharmacol 2013;17:116-22.
54. Zhao J, Wang H, Dai C, et al. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 2013;65:3176-85.
55. Tsai PY, Ka SM, Chang JM, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011;51:744-54.
56. Yuan Y, Liu Z. Isoflurane attenuates murine lupus nephritis by inhibiting NLRP3 inflammasome activation. Int J Clin Exp Med 2015;8:17730-8.
57. Kahlenberg JM, Yalavarthi S, Zhao W, et al. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol 2014;66:152-62.
58. Yang Q, Yu C, Yang Z, et al. Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus. J Rheumatol 2014;41:444-52.
59. Yang CA, Huang ST, Chiang BL. Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages. Rheumatology 2015;54:324-31.
60. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213-24.
61. Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology 2007;46:1052-6.
62. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in antidouble-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634-43.
63. Austin HA3rd, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-50.
64. Austin HA3rd, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
65. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
66. Tarr T, Derfalvi B, Gyori N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus 2015;24:796-803.
67. Zappitelli M, Duffy CM, Bernard C, et al. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol 2008;23:83-91.
68. Mak A, Mok CC, Chu WP, et al. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007;16:28-34.
69. Niewold TB, Adler JE, Glenn SB, et al. Age-and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008;58:2113-9.
70. Fantuzzi L, Puddu P, Varano B, et al. IL-18 exert opposite regulatory effects on the IL-12 receptor expression and IL-12-induced IFN-gamma production in mouse macrophages: novel pathways in the regulation of the inflammatory response of macrophages. J Leukoc Biol 2000;68: 707-14